wegovy and tirzepatide Diabetes drug linked to more significant weight loss than semaglutide Weight loss drugs like Mounjaro

En octubre del 2025 la FDA amplio la indicacin de simaglutida para la reduccin del riesgo de eventos cardiovasculares mayores (muerte cardiovular, infarto al miocardio no fatal, ataque vascular no fatal) en adultos con diabetes mellitus tipo 2 (no insulinodependiente) que tienen riesgo alto de desarrollar estos eventos

With regular use, many people notice gradual improvements in how they feel during the day

Importantly, there is no established direct pharmacological link between tirzepatide itself and hair follicle damage

Not for human use Not for veterinary use Not for diagnostic use Not for therapeutic or medical use Not for food, drug, cosmetic, or dietary supplement applications By purchasing this product, the purchaser acknowledges that the compound will be used only in a controlled research environment by qualified professionals and in accordance with applicable regulations